Table 1 Clinical characteristics of the participants
From: Gut microbiome changes in anti-N-methyl-D-aspartate receptor encephalitis patients
| Â | Â | Anti-NMDAR encephalitis (n=10) | Healthy controls (n=10) | P-value |
|---|---|---|---|---|
Epidemiology | Age (years ± SD) | 30.4± 12.1 | 32.2 ± 11.6 | 0.738 |
Female/male | 4/6 | 6/4 | 0.656 | |
Weight (kg ± SD) | 66.7 ± 8.3 | 64.8 ± 10.1 | 0.658 | |
Height (m ± SD) | 1.67 ± 0.07 | 1.68 ± 0.10 | 0.782 | |
Body mass index (kg/m2 ± SD) | 23.7 ± 1.3 | 22.7±2.0 | 0.184 | |
Medication | Antibiotics (last 6 months) | 1 | 0 | 1.000 |
Immunosuppression (last 6 months) | 2 | 0 | 0.474 | |
Hypertensive | 0 | 0 | - | |
Thyroid Dysfunction | 0 | 0 | - | |
Proton pump inhibitor | 1 | 0 | 1.000 | |
Diabetes | 0 | 0 | - | |
Anticoagulation | 0 | 0 | - | |
Medical condition | Seizure (last 6 months) | 2 | 0 | 0.474 |
Anti-epileptic drugs | 1 | 0 | 1.000 | |
Cognitive impaired | 2 | 0 | 0.474 | |
Unconscious | 1 | 0 | 1.000 | |
Pregnant | 0 | 0 | - | |
Diarrhea | 0 | 0 | - | |
Constipation | 0 | 0 | - |